NurExone Biologic is developing a revolutionary biological exosome based technology drug platform to treat damage in the Central Nerve System.The breakthrough exosome-based technology was proven in preclinical studies to have the potential to treat spinal cord injuries.

NurExone Biologic (TSXV: NRX) (FSE: J90)

Head of Bioprocess Development

Process Development Director

QC Director

Development Director

R&D Projects Manager

Research Assistant

Head of CMC ,Quality and Regulatory

Director of Research

VP Product Development

Vice President R&D

Director of Research and  Development

Director of Neuroscience

Project Manager

Research And Development Scientist

Research Scientist

Process Development Associate

R&D Student

SRE Team Leader

Operations Supervisor

Operations Team Member

Chief Financial Officer

Lecturer in Bar-Ilan University

Chief Financial Officer and Director of Silenseed China (Subsidiary of Silenseed Ltd.)

Mergers and Acquisitions Manager

Senior Finance Director

Founder and Chief Executive Officer

VP Finance

Finance Manager

Financal Controller

Chief Executive Officer

Initiator and Head of the BioMed-MBA program

Partner at Hollyhigh International Capital; VP Technology Scouting, Innovation and Partnership WW

VP Technology Scouting, Innovation & Partnerships in Israel

Head of Research and Development

Senior Project Manager and Research Scientist

Co-Founder

PhD researcher

Visiting Ph.D. student

Research assistant

Laboratory assistant

Staff Sergeant, Full military service

Director of R&D

Bioanalytics Field Leader

Small Molecules Project Leader

Senior Assay Development Scientist

Teacher Assistant

QA Tester

Researcher

Development Scientist

Co-Founder and CEO

Translational science and Tech-transfer specialist

Head Of Research And Development

Senior Scientist

Senior Manager for Strategic R&D Projects

Founder / CEO

Gmail

Google Apps

Google Tag Manager

Mobile Friendly

reCAPTCHA

Google Analytics

Minovia Therapeutics is a clinical-stage international biotechnology company, established in hopes to bring life changing therapies to patients with Mitochondrial diseases, as fast as responsible. Following compassionate use cases performed in Sheba Medical hospital in Israel, using our proprietary Mitochondrial Augmentation Therapy, Minovia is now conducting the first of its kind clinical trial for Pearson syndrome, an ultra-rare pediatric disease.

Minovia Therapeutics

WordPress.org

Nginx

NanoGhost is a biotech company that develops a highly selective first-in-class drug delivery platform (Nano-Ghosts/NGs) from the cell membrane of mesenchymal stem cells (MSCs), cells with known tropism to cancer and sites of inflammation.NanoGhost offers a novel, versatile, and highly selective targeted drug delivery platform for the treatment of oncological diseases.NanoGhosts can be loaded with various drug types, preserve MSCs tropism to cancer cells, and selectively penetrate tumors (including brain tumors while crossing the BBB and pancreatic cancer), leading to a major reduction in tumor size and prolonged survival.

NanoGhost

Outlook

Google Cloud Hosting

Varnish

MeMed is a leading med tech and bio-convergence company, having developed innovative diagnostic host immune response testing methods that address complex clinical dilemmas and improve patient outcomes.Our mission is to translate the complex signals of the immune system into simple diagnostic insights that transform the way we treat infectious diseases and inflammatory disorders – at the right place and the right time.

Global Marketing Lead - US

Senior Marketing Manager

Senior Marketing Manager - Israel

MeMed

Pardot

Atlassian Cloud

DoubleClick Conversion

DoubleClick

Approximately 36 years before Israel declared independence, a ceremony took place on the barren slopes of Mount Carmel near the Port of Haifa, which was then occupied by the Ottoman Empire. Unknown to the Haifa community witnessing the event, this would be a milestone in history. This first cornerstone embodied an implausible vision of creating a world-class institute of scientific and technological education in the Holy Land.The story of the "Technikum" – the original German name of the Technion – is a tale of the century. The second industrial revolution created the printing presses and communications infrastructure allowing Jews scattered around the globe to organize in face of rising anti-Semitism. As Jews were often barred from technical education, the establishment of a technical school was a first priority to rebuilding a Jewish homeland. The Technion was to become a unique worldwide university that would precede, create, shape, and protect a modern state.The cornerstone laid on April 11, 1912, set in motion a century of progress responding to national and global needs. Technion – Israel Institute of Technology would grow rapidly, becoming a global pioneer in fields such as biotechnology, stem cell research, space, computer science, nanotechnology, and energy. Four Technion professors have won Nobel Prizes. As it approaches its centennial in 2025 – 100 years after the first class took place – Technion City is a thriving world center of trailblazing excellence in research and teaching for the benefit of humanity, with 18 faculties, more than 14,000 students, 135 academic programs, and 60 research institutes. Since the Technion opened its doors, more than 90,000 Technion alumni have played a huge part in creating and leading the ‘Startup Nation,' impacting the lives of millions of people worldwide.

PhD and MSc positions

Lab Engineer

Technion - Israel Institute of Technology

Microsoft Office 365

Workday Recruit

SiteScout

Google AdSense

Rafael Advanced Defense Systems Ltd. is synonymous with dynamic defense, daring innovation, and technological ingenuity. For over 70 years, the company has pioneered advances in defense solutions for air, land, sea, space, and cyber. Our innovations are based on extensive operational experience and understanding of evolving combat requirements. They enable the rapid development of effective solutions for complex challenges on a variety of fronts. Always ahead ‒ we ensure ongoing advantages for our global client base. We are dedicated to continuously enhancing our customer service, as well as expanding our global industrial cooperation programs.

Noa Avni

Director of R&D at NurExone Biologic (TSXV: NRX) (FSE: J90)

Noa Avni's Professional Contact Details

Noa Avni's Current Company Details

NurExone Biologic (TSXV: NRX) (FSE: J90)

Noa Avni's Work History and Education

Others Named Noa Avni

Frequently Asked Questions about Noa Avni

What company does Noa Avni work for?

What is Noa Avni's role at NurExone Biologic (TSXV: NRX) (FSE: J90)?

What is Noa Avni's email address?

What is Noa Avni's business email address?

What is Noa Avni's HQ phone number?

What industry does Noa Avni work in?

Who are Noa Avni's colleagues?

Colleagues at NurExone Biologic (TSXV: NRX) (FSE: J90)

Prospect on LinkedIn

People Search

Company Search

Erik Straub

Michael Transon

Ready to try it out?